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Abstract
Chronic use of methamphetamine (METH) leads to long-lasting cognitive dysfunction in humans 
and in animal models. Modafinil is a wake-promoting compound approved for the treatment of 
sleeping disorders. It is also prescribed off label to treat METH dependence. In the present study, 
we investigated whether modafinil could improve cognitive deficits induced by sub-chronic 
METH treatment in mice by measuring visual retention in a Novel Object Recognition (NOR) 
task. After sub-chronic METH treatment (1 mg/Kg, once a day for 7 days), mice performed the 
NOR task, which consisted of habituation to the object recognition arena (5 min a day, 3 
consecutive days), training session (2 equal objects, 10 min, day 4), and a retention session (1 
novel object, 5 min, day 5). One hour before the training session, mice were given a single dose of 
modafinil (30 or 90 mg/Kg). METH-treated mice showed impairments in visual memory retention, 
evidenced by equal preference of familiar and novel objects during the retention session. The 
lower dose of modafinil (30 mg/Kg) had no effect on visual retention scores in METH-treated 
mice, while the higher dose (90 mg/Kg) rescued visual memory retention to control values. We 
also measured ERK phosphorylation in medial prefrontal cortex (mPFC), hippocampus, and 
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nucleus accumbens (NAc) of METH- and vehicle-treated mice that received modafinil 1 hr before 
exposure to novel objects in the training session, compared to mice placed in the arena without 
objects. Elevated Extracellular signal-regulated kinase (ERK) phosphorylation was found in the 
mPFC of vehicle-treated mice, but not in METH-treated mice, exposed to objects (p<0.05). The 
lower dose of modafinil had no effect on ERK phosphorylation in METH-treated mice, while 90 
mg/Kg modafinil treatment restored the ERK phosphorylation induced by novelty in METH-
treated mice to values comparable to controls (p<0.05). We found neither a novelty nor treatment 
effect on ERK phosphorylation in hippocampus or nucleus accumbens (NAc) of vehicle- and 
METH-treated mice receiving acute 90 mg/Kg modafinil treatment. Our results showed a 
palliative role of modafinil against METH-induced visual cognitive impairments, possibly by 
normalizing ERK signaling pathways in mPFC. Modafinil may be a valuable pharmacological tool 
for the treatment of cognitive deficits observed in human METH abusers as well as in other 
neuropsychiatric conditions.
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INTRODUCTION
Methamphetamine (METH) is a psychostimulant with a high potential for abuse and 
addiction. Repeated exposure to METH causes abnormal changes in neurotransmitter 
activity involved in learning, reward, and executive function (Bamford et al., 2008; 
Feltenstein and See, 2008). METH also alters neuronal plasticity in brain regions that 
mediate cognition and motivation (Kauer and Malenka, 2007; Robinson and Kolb, 2004). 
METH addiction generally begins with recreational use and progresses over time into a 
compulsive and chronically relapsing disorder, accompanied by psychiatric symptoms 
including hallucinations and delusions, as well as long-term cognitive deficits (Scott et al., 
2007). METH-dependent individuals exhibit high rates of cognitive dysfunction in several 
neuropsychological domains that include sustained attention, episodic memory, information 
processing, and impulse control (Monterosso et al., 2005; Nordahl et al., 2003; Simon et al., 
2010; Morgan et al., 2012). These cognitive deficits might undermine efforts by METH 
addicts to stop or reduce METH use and negatively affect the outcome of treatment (Vocci 
and Appel, 2007). Given the potential links between cognition and treatment outcome in 
METH dependence, therapeutic approaches that improve cognitive function may be quite 
promising in the management of METH addiction.
Modafinil (Provigil) is a psychostimulant and cognitive enhancer drug, approved by the U.S. 
Food and Drug Administration for treating narcolepsy and other sleep disorders. Different 
studies showed that modafinil cognitive-enhancing properties improved outcome in the 
treatment of pathologic gamblers (Zack and Poulos, 2009), alcoholics (Schmaal et al., 2013), 
and patients suffering from other neuropsychiatric conditions (Scoriels et al., 2013). The use 
of modafinil as a treatment for cocaine and METH dependence remains inconclusive, with 
studies showing positive outcomes (Dackis et al., 2005; McGough et al., 2009) and studies 
showing promising but yet non-significant results in reducing drug use (Dackis et al, 2012; 
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Shearer et al., 2009; Heinzerling et al., 2010). For both cocaine and METH users, modafinil 
was efficacious in improving several domains of cognitive and executive functions 
(Kalechstein et al, 2013; Gharemani et al., 2011; Kalechstein et al., 2010; Hester et al., 
2010; Finke et al., 2010).
Modafinil’s mechanism of action, although somewhat poorly understood, appears to involve 
multiple neurotransmitter systems. For example, modafinil can act as a weak DA transporter 
(DAT) inhibitor that increases extracellular DA levels (Mereu et al. 2013). Modafinil 
influences GABAergic, glutamatergic, noradrenergic, serotoninergic, histaminergic, and 
orexinergic systems (for a review see Mizenberg and Carter, 2008, Scoriels et al., 2013). In 
addition, modafinil enhances electrotonic coupling by increasing the effectiveness of gap 
junctions between neurons (Urbano et al., 2007; Garcia-Rill et al., 2007). We also 
demonstrated that modafinil can protect against METH toxicity (Raineri et al., 2011; 2012). 
Specifically, modafinil was able to prevent METH-induced toxic effects that included DA 
depletion and reductions in tyrosine hydroxylase (TH) and DAT levels in the striatum 
(Raineri et al., 2011). Furthermore, modafinil also attenuated METH-induced hyperthermia, 
glial activation, and increased expression of proapoptotic proteins (Raineri et al., 2012).
Compared to classical psychostimulants such as cocaine or amphetamine, the sites of action 
and behavioral effects of modafinil appear to be different (Mereu et al., 2013). Modafinil 
showed lower liability to abuse and lower risk of adverse effects on organ systems including 
the cardiovascular system (Minzenberg and Carter, 2008). Clinically relevant modafinil 
doses can robustly activate fronto-cortical areas involved in higher cognitive functions and a 
network of pro-arousing areas, which provide a plausible substrate for the wake-promoting 
and pro-cognitive effects of the drug (Gozzi et al., 2012). Of relevance to the present study, 
METH-dependent subjects showed a greater effect of modafinil on brain activation in 
bilateral insula/ventrolateral prefrontal cortex and anterior cingulate cortices than control 
participants, suggesting that modafinil improves learning in METH-dependent participants 
by enhancing neural function in those regions (Ghahremani et al., 2011).
The intracellular signaling pathways that mediate modafinil actions in fronto-cortical areas 
remain unknown. A potential candidate is the mitogen-activated protein kinase extracellular 
signal-regulated kinase (MAPK-ERK) cascade. The ERK1/2 pathway plays a critical role in 
memory function under physiological and pathological conditions (Mizoguchi et al. 2004; 
Kamei et al. 2006; Nagai et al. 2007, Cammarota et al., 2008). ERK1/2 signaling pathway 
linked to dopamine D1 receptors (Valjent et al., 2000; Zanassi et al., 2001) is involved in 
METH-associated contextual memory in rats (Mizoguchi et al., 2004). Additionally, it has 
been demonstrated that repeated METH treatment in mice induced cognitive impairment in a 
novel object recognition test, which was associated with deficits of the ERK1/2 pathway in 
the prefrontal cortex (PFC) (Kamei et al., 2006).
As it was mentioned above, there is only limited information on the mechanisms by which 
modafinil improves cognition in patients with addictive behaviors in terms of underlying 
neural substrates. Therefore, in the present study, we designed experiments aimed at testing 
modafinil’s ability to improve cognitive deficits induced by sub-chronic METH treatment in 
mice. We used a novel object recognition (NOR) task, which is similar to visual recognition 
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tests widely used in subhuman primates (Ennaceur, 2010), and is sensitive to METH-
induced cognitive impairments (Bisagno et al., 2002; Kamei et al., 2006; Reichel et al., 
2011). The NOR task evaluates the rodents’ ability to recognize a novel object in the 
environment, and discrimination and memory performance is obtained upon identification of 
familiarity and novelty (Antunes and Biala, 2012). So, we also examined how modafinil and 
METH differentially modulated fronto-cortical phosphorylation of the MAPK isoforms, 
ERK1/ERK2 following exposure to novelty.
MATERIALS AND METHODS
Animals
C57BL/6 male mice (2–3 month-old) from the School of Exact and Natural Sciences of the 
University de Buenos Aires (UBA) were housed in a light and temperature-controlled room 
(12-h light/dark cycle, 22 °C), and were given free access to laboratory chow and tap water. 
Principles of animal care were followed in accordance with “Guidelines for the Care and 
Use of Mammals in Neuroscience and Behavioral Research” (National Research Council, 
2003) and approved by Universidad de Buenos Aires authorities (Protocol Number: 
A5801-01) using OLAW and ARENA directives (NIH, Bethesda, USA).
Pharmacological reagents
Drugs were purchased from either Sigma (St. Louis, MO) or Tocris (Ellisville, MO). 
Modafinil (racemic mixture of R- and S-enantiomers) was generously donated by 
Laboratorios Beta S.A. (Argentina).
Drug treatments
(+)-Methamphetamine hydrochloride (Sigma, St Louis, MO) was administered 
subcutaneously (sc) once a day for 7 days (1 mg/Kg, calculated as free base, dissolved in 
sterile saline solution). The METH regimen used in this study was performed according to 
studies by Kamei et al., (2006). Four days after the last METH injection, modafinil (30 or 90 
mg/Kg, dissolved in DMSO-Arabic gum 5% in sterile saline solution) was injected and 1 
hour later mice were subjected to behavioral analysis (Novel Object Recognition task or 
Novelty exposure, Figure1A and 1B). Vehicle groups received the same volume of sterile 
saline and DMSO/Arabic gum/saline. Drugs were injected at a volume of 10 ml/Kg of body 
weight.
Novel Object Recognition (NOR) task
The NOR task was adapted according to previously reported methods (Kamei et al., 2006). 
The NOR task evaluates the rodents’ ability to recognize a novel object in the environment. 
Basically, in the NOR task, there are no positive or negative reinforcers, and this 
methodology assesses the natural preference for novel objects displayed by rodents 
(Ennaceur, 2010). The task procedure consists of three phases: habituation, training, and a 
test phase. In the habituation phase, each animal is allowed to freely explore the arena in the 
absence of objects. The animal is then removed from the arena and placed in its cage. 
During the training phase, a single animal is placed in the arena containing two identical 
sample objects (A + A) for 5 minutes. The experimental context is not drastically different 
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during the training and the test phase. After a retention interval begins the test phase, and the 
animal is returned to the arena with two objects, one is identical to the sample and the other 
is novel (A + B). In our experiments, exploration occurred in an open-top arena (40 cm3) 
made of plexiglass, with the floor covered with clean woodchip bedding. Testing was done 
during the light phase (8 AM– 8 PM), in a sound-attenuated room, with dimmed 
illumination (40 W). Mice were individually habituated to the box for 5 min during three 
consecutive days after the last METH injection, in the absence of objects (Figure 1B: 
habituation sessions, withdrawal days 1–3). On the fourth day after METH, two identical 
objects were symmetrically fixed to the floor of the box, 8 cm from one of the walls, and 
each mouse was allowed to explore the box for 10 min (Figure 1B: training session, 
withdrawal day 4). Objects were: golf balls, plastic pipes (3 cm diameter, 8 cm high) and 
plastic cubes (4 cm3), all of which were similar in size but different in color, shape and 
brightness. Sets of objects were chosen based on preliminary experiments that indicated that 
they were similarly preferred. Objects were washed with 40% ethanol solution between 
trials. Following a 24-hour delay, mice were placed back in the box for 5 min where one of 
the familiar objects was replaced by a novel object (Figure 1B: retention session, withdrawal 
day 5). The positions of the objects in the test and the objects used as novel or familiar were 
counterbalanced between the animals in each group and between the control and drug-
treated groups. All sessions were recorded and analyzed with Ethovision XT 7.0 tracking 
software (Noldus, The Netherlands), using nose point-tail base detection. The percentage of 
exploratory preference (%EP) was calculated as exploration time of the novel object (TN) 
divided by the total exploration time of both novel (TN) and familiar (TF) objects 
[%EP=TN/(TN+TF)*100]. Similarly, this calculation can be applied when both objects are 
identical, in the training session phase, but here the mathematic formula will be exploration 
time of the right object (TR) divided by the total exploration time of both right (TR) and left 
(TL) objects [%EP=TR/(TR+TL)*100].
Novelty effect
In a separate set of experiments, mice were individually habituated to object recognition box 
for 5 min during three consecutive days after the last METH injection (in the absence of 
objects). On the METH withdrawal day 4, mice were placed in the arena for 10 minutes with 
objects (Novelty) or without objects (Control) (Figure 1B), and then immediately 
euthanized. Brains were quickly removed and brain areas were dissected out on an ice-cold 
plate. Each tissue sample was frozen and stored at −70 °C until processed.
Exploratory activity
We investigated the effect of early METH withdrawal on exploratory activity. Spontaneous 
locomotor activity was recorded during habituation sessions to the object recognition arena 
using Ethovision XT 7.0 tracking software (Noldus, The Netherlands). We analyzed 
locomotor activity (distance travelled) and time spent in the center area of the arena during 
the 5-min habituation sessions. The center area was defined as one half the total area of the 
arena.
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We measured ERK and phosphorylated ERK (pERK) protein expression by Western blot in 
brain areas of mice subjected to the novelty effect. Brains were removed rapidly after 
Novelty and Control sessions and brain sections were dissected out and stored at −70 °C. 
Tissue homogenates were prepared in a solution containing 50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 0.1% Triton X100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 5 µg/ml 
leupeptin, and 5 µg/ml aprotinin. After removal of cell debris by centrifugation, the protein 
concentration of the cell lysate was determined. The homogenates were combined with 
loading buffer containing 4% SDS, 20% glycerol, 10% β-mercaptoethanol, 125 mM Tris, 
(pH 6.8), and boiled at 100 °C for 5 min. Protein samples (50 µg) were separated by 12.5% 
SDS-PAGE, and the separated proteins transferred to a PVDF membrane. Immunoblotting 
was performed using a mouse monoclonal antibody to pERK1/2 (1:500, E-4 sc-7373 Santa 
Cruz Biotechnology), then membranes were stripped and reprobed with polyclonal rabbit 
antibody to total ERK2 (1:2000, C-14 sc-154 Santa Cruz Biotechnology). Because there was 
no change in the levels of total ERK, values of pERK were normalized to the values of total 
ERK. Immune complexes were detected with anti-mouse and anti-rabbit secondary 
antibodies and chemiluminescence reagents (Amersham, NJ, USA). Bands were quantified 
using ImageJ (NIH).
Statistical analysis
InfoStat software (www.infostat.com.ar) was used for statistical comparisons. Statistics were 
performed using either one-way (treatment) or two-way (novelty and treatment) ANOVA 
followed by Bonferroni post hoc tests or planned contrasts. Data were transformed when 
required. Kruskal Wallis ANOVA on Ranks was performed when data did not comply with 
the assumptions of parametric tests. For the analysis of exploratory activity during 
habituation sessions, repeated measures two-way ANOVA followed by Bonferroni was 
performed. Differences were considered significant if p<0.05.
RESULTS
1. Effects of modafinil and methamphetamine on exploratory activity and object 
recognition memory
1.a Effect of methamphetamine withdrawal on exploratory activity—As shown in 
Figure 1A, mice were treated with a chronic METH or vehicle protocol (METH 1 
mg/Kg/day for 7 consecutive days). Next, mice were placed in an object recognition arena 5-
min a day for 3 consecutive days, as part of the habituation sessions for the NOR task. We 
recorded these habituation sessions and analyzed exploratory activity during METH 
withdrawal, measuring locomotion and time spent in the center of the arena (Figure 2). 
Repeated measures two-way ANOVA for locomotion showed significant day effect 
[F(2,50)=21.75, p<0.001], but no treatment or interaction effect (Figure 2A). Bonferroni 
post hoc test showed that on day 1 of withdrawal both METH- and vehicle-treated mice 
manifested increased locomotion (p<0.05), compared to day 2 and 3, suggesting habituation 
to the object recognition arena. Repeated measures two-way ANOVA for time in center 
showed significant treatment [F(1,50)=5.14, p<0.05], day [F(2,50)=18.81, p<0.001], and 
interactive [F(2,50)=3.69, p<0.05] effects (Figure 2B). Bonferroni post hoc test showed that 
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on day 2 the Vehicle group diminished the time spent in the center (p<0.05), while the 
METH group did not. On day 3 both groups spent similar amounts of time exploring the 
center. These results indicate that, by the time training sessions of the NOR task had started, 
both METH and control mice showed similar exploratory activity and were similarly 
habituated to the object recognition arena.
1.b Acute modafinil effects on methamphetamine withdrawal: object 
recognition memory—On day 4 of withdrawal, mice received acute vehicle, 30 or 90 
mg/Kg modafinil dose and 1 hr later performed the training session of the NOR task. As 
expected, one way ANOVA found no significant differences in the exploratory preference 
for the training sessions after either 30 or 90 mg/Kg modafinil (Figure 3A and B). The 
retention session was performed 24 hrs later, and both 30 mg/Kg and 90 mg/Kg modafinil 
groups showed significant treatment effect (modafinil 30 mg/Kg: Kruskal Wallis ANOVA on 
ranks [H=10.26, p<0.05]; modafinil 90 mg/Kg retention session: one way ANOVA-
Bonferroni [F(3,70)=8.11, p<0.001]). For both 30 and 90 mg/Kg groups, post hoc tests 
showed impaired object recognition memory in METH-treated mice, evidenced by similar 
preference of familiar and novel objects during the retention session of the NOR task (Figure 
3A and B). Acute 30 mg/Kg modafinil did not improve object recognition deficits observed 
in METH-treated mice (Figure 3A). Modafinil at a higher dose, 90 mg/Kg, improved 
METH-induced object recognition deficits, evidenced by a significant increase in the 
preference index in the METH-MOD group compared to the METH group (p<0.05), to 
values comparable to those of the Vehicle group (Figure 3B). Modafinil-treated subjects (for 
30 and 90 mg/Kg) showed preference values similar to the Vehicle group, and significantly 
higher compared to those of the METH group (p<0.05). Total time spent in object 
exploration during the training and retention sessions did not differ among groups for the 
two modafinil doses (Figure 3C and D). These results suggest that chronic METH treatment 
did not have an effect on motivation and exploration, suggesting METH-induced memory 
impairment rather than a lack of interest in novel stimuli. We also measured locomotor 
activity during training and retention sessions (Figure 3E and F). Both 30 mg/Kg and 90 
mg/Kg modafinil groups showed significant treatment effect in the training session (MOD 
30 mg/Kg: one way ANOVA-Bonferroni [F(3,38)=11.45, p<0.001]; MOD 90 mg/Kg: one 
way ANOVA-Bonferroni [F(3,77)=66.47, p<0.001]). Post hoc tests showed no differences in 
locomotor activity of Vehicle- and METH-treated mice, while the acutely MOD-treated mice 
(MOD and METH-MOD groups) showed an increase in locomotor activity compared to 
Vehicle and METH groups at both modafinil doses (p<0.05). It is noteworthy that the 90 
mg/Kg the METH-MOD group exhibited higher locomotor activity compared with 
modafinil group values (p<0.05) (Figure 3E). One way ANOVA found no significant 
differences in locomotion for the retention sessions in either 30 or 90 mg/Kg modafinil 
groups. In addition, modafinil-induced improvement of object recognition memory deficits 
after METH was replicated in female mice (data not shown). We used the same protocol 
previously described for male mice using modafinil at a dose that showed positive results, 
i.e. 90 mg/Kg. Exploratory preferences in retention session (%) were as follows: Vehicle: 
65.01±4.20 [a], MOD: 66.34±3.61 [a], METH: 44.91±8.41 [b], METH-MOD: 66.21±7.01 
[a], one way ANOVA-Bonferroni [F(3,24)=3.02, p<0.05].
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2. Effects of modafinil and methamphetamine locomotor activity and ERK phosphorylation 
induced by novelty
The results obtained in the NOR task showed that modafinil, given at a high 90 mg/Kg dose 
before the first exposure to novel objects, was able to enhance long-term memory retention 
by restoring the novelty preference in a retention session performed 24 hrs later. As 
mentioned above, the NOR task evaluates the rodents’ ability to recognize a novel object in 
the environment and discrimination and memory performance is obtained upon 
identification of familiarity and novelty (Antunes and Biala, 2012). Novelty is a change from 
expected likelihood of an event on the basis of both previous information and internal 
estimates of conditional probabilities (Antunes and Biala, 2012). Animals can be affected by 
a novel stimulus; i.e. novelty can change the animals’ behavior, induce stress responses, and 
elicit approach behavior (Bevins et al., 2002). Therefore, we conducted separate experiments 
in mice subjected to METH withdrawal aimed at investigating novelty-induced changes on 
mPFC ERK phosphorylation and exploratory activity with or without modafinil 
administration.
2.a Effect of acute modafinil on mice exposed to novel objects during 
methamphetamine withdrawal: locomotor activity—To asses novelty-induced 
locomotor activity, mice were placed in the arena with or without objects (Novelty and 
Control groups, respectively) for 10 min, and euthanized immediately (Figure 1B). We 
recorded Control and Novelty sessions and analyzed locomotor activity. For the 30 mg/Kg 
modafinil group, two way ANOVA showed significant treatment effect [F(3,33)=56.45, 
p<0.001], but no novelty or interactive effects. For the 90 mg/Kg modafinil group, two way 
ANOVA showed significant treatment [F(3,62)=53.30, p<0.001], novelty [F(1,62)=10.43, 
p<0.01], and interactive [F(3,62)=3.33, p<0.05] effects. Bonferroni post hoc tests 
demonstrated that Vehicle and METH groups showed neither treatment nor novelty effects 
on locomotion (Figure 4A and B). Mice given acute 30 mg/Kg modafinil displayed only a 
main treatment effect, evidenced by MOD and METH-MOD groups showing increased 
locomotion compared with Vehicle and METH groups (Figure 4A). In agreement with 
locomotor responses obtained in mice while performing the NOR task (Figure 3E), the 
MOD and METH-MOD groups receiving 30 mg/Kg modafinil showed similar locomotor 
effects. In mice receiving acute 90 mg/Kg MOD (Figure 4B), we found elevated locomotion 
in the MOD and METH-MOD groups compared to Vehicle and METH groups; also, with 
the 90 mg/Kg dose the METH-MOD group showed higher locomotion than the MOD group. 
This is in agreement with locomotor responses obtained for the same dose in the NOR task 
(Figure 3F). We also found within the METH-MOD group increased locomotion in the 
novelty group when compared to the control group (p<0.05).
2.b Effect of acute modafinil on mice exposed to novel objects during 
methamphetamine withdrawal: ERK phosphorylation in mPFC—It was 
previously shown that one of the molecular mechanisms involved in METH-induced object 
recognition deficits involve a failure in mPFC ERK phosphorylation after exposure to novel 
objects (Kamei et al., 2006). Thus, we decided to investigate if modafinil would be able to 
restore ERK signaling pathway in the mPFC after a Novelty exposure. For both 30 mg/Kg 
and 90 mg/Kg modafinil experiments, two way ANOVA showed significant novelty effect 
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[modafinil 30 mg/Kg: F(1,35)=5.41, p<0.05; modafinil 90 mg/Kg: F(1,47)=10.33, p<0.01], 
but no treatment or interactive effects. For both experiments, planned contrasts comparing 
control vs. novelty within each treatment revealed a significant increase in ERK 
phosphorylation in the mPFC of the Vehicle and MOD groups immediately after the Novelty 
session (p<0.05), which was abolished in the METH group. We found that, in agreement 
with the retention results obtained in the NOR task, METH-MOD group receiving acute 30 
mg/Kg modafinil showed no novelty-induced increase in ERK phosphorylation (Figure 5A). 
In mice that received 90 mg/Kg modafinil we observed that the novelty-induced ERK 
phosphorylation was restored (p<0.05) (Figure 5B). The levels of total ERK did not differ 
between experimental groups in any case [modafinil 30 mg/Kg: F(7,35)=1.75, p>0.05; 
modafinil 90 mg/Kg: F(7,47)=1.00, p>0.05].
2.c Effect of acute modafinil on mice exposed to novel objects during 
methamphetamine withdrawal: ERK phosphorylation in the NAc and 
hippocampus—The hippocampus participates in the formation and consolidation of new 
memories and it was previously shown that MAPK and ERK play important roles 
(Cammarota et al., 2008). Therefore, we measured novelty-induced ERK phosphorylation in 
the hippocampus of METH-treated mice, with or without an injection of 90 mg/Kg 
modafinil (Figure 6A). We found no changes in ERK phosphorylation in the hippocampus in 
any group subjected to the novelty effect [F(7,31)=1.00, p>0.05] (Figure 6A). The levels of 
total ERK did not differ between experimental groups in any condition [F(7,31)=1.24, 
p>0.05].
There is evidence suggesting that the NAc is involved in the behavioral response to novelty 
and other tasks that rely on familiarity discrimination (Sargolini et al., 2003; Nelson et al., 
2010). Therefore, we evaluated novelty-induced ERK phosphorylation in the NAc of 
METH-treated mice, with or without an injection of 90 mg/Kg modafinil (Figure 6B). We 
found no changes in ERK phosphorylation in NAc in any group subjected to the novelty 
effect [F(7,26)=0.35, p>0.05]. The levels of total ERK did not differ between experimental 
groups in any condition [F(7,26)=0.96, p>0.05].
DISCUSSION
The main finding of this study is that acute modafinil administration improved METH-
induced object recognition memory deficits. METH-treated mice also showed a failure in 
ERK phosphorylation in the mPFC, which, in rodents, is detected shortly after a novel object 
is presented for exploration (Kamei et al., 2006; Nagai et al., 2007). Modafinil 
administration also restored novelty-induced ERK phosphorylation in the mPFC. To our 
knowledge, this is the first study addressing modafinil’s beneficial effects on the visual 
recognition deficits induced by METH in an animal model. Modafinil also showed positive 
effects in animal models of neurodegeneration (Garcia et al., 2013). Interestingly, modafinil 
did not modify cognition in naïve rats but was able to reverse memory deficits induced by 
iron overload, a model of memory impairment related to neurodegenerative disorders 
(Garcia et al., 2013). Furthermore, these authors used several doses of MOD (0.75, 7.5 or 75 
mg/Kg) and found that only the highest dose tested (75 mg/Kg) was able to restore object 
recognition deficits (Garcia et al., 2013). These data are in agreement with results from the 
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present study since we have observed that modafinil was only effective at a dose of 90 
mg/Kg, while 30 mg/Kg modafinil did not show protective effects. Our results are also in 
agreement with previous studies in humans, where modafinil administration was able to 
improve cognitive deficits and prefrontal cortical function only in METH-dependent subjects 
(Gharemani et al., 2011). Additionally, it has been shown that modafinil is more effective in 
individuals who perform poorly on cognitive tasks relative to those subjects who perform 
better, indicating that modafinil does not enhance baseline performance but improves 
cognition in subjects with evident cognitive impairments (Kalechstein et al., 2010; Finke et 
al., 2010). Recent clinical studies showed that modafinil oral administration in METH users 
with 7 days of abstinence, at a dose recommended for the treatment of sleeping disorders 
(200 mg, once daily), although improved several domains of executive function, had no 
effect on visual memory performance (Hester et al., 2010). Accordingly, Finke and co-
workers (2010) showed improved visual processing in participants with low performance 
baseline when using a higher modafinil dose (400 mg once daily). All together, these results 
from clinical and pre- clinical studies suggest that a high dose of modafinil might be needed 
in order to achieve improvements in cognitive functions.
The mPFC mediates executive function and decision making processes, and is therefore a 
key neuroanatomical region in addictive behaviors (Schoenbaum and Shaham, 2008). 
Studies using functional magnetic resonance imaging have shown that PFC dysfunction in 
METH abusers is associated with cognitive impairment (Paulus et al., 2002), probably 
linked to deficits in DA neurotransmission (Tritsch and Sabatini, 2012). Although the effects 
of modafinil on midbrain DA neuronal activity remain inconsistent, modafinil acts as a weak 
DAT inhibitor (Mereu et al., 2013). Consequently, it has been shown that acute modafinil 
administration increased extracellular DA levels in the mPFC (de Saint Hilaire et al., 2001), 
the striatum of rodents (Dopheide et al., 2007; Nguyen et al., 2011; Young et al., 2011) and 
humans (Volkow et al., 2009). Acute modafinil also induced a strong activation in those 
areas, measured using PET and confirmed by c-Fos immunoreactivity (Gozzi et al., 2012). 
Modafinil was also found to rescue visual object recognition in a rat model of schizophrenia 
(Redrobe et al., 2010), which is a condition that presents with diminished dopamine 
neurotransmission in PFC (Okubo et al., 1997). Thus, modafinil’s ability to enhance 
cognitive performance in METH abusers might be associated with modafinil’s actions on the 
DAT (Mereu et al. 2013), stimulating dopaminergic neurotransmission in the 
mesocorticolimbic system.
It is known that ERK, a member of the MAPK family, is critically linked to dopaminergic 
neurotransmission and long-term memory retention, but not memory acquisition or short 
term memory (Valjent et al 2000; Nagai et al., 2007). ERK signaling is activated by stimuli 
associated with synaptic activity and plasticity, like calcium influx and neurotrophins, and its 
activation mediates, in part, new mRNA and protein synthesis necessary for long-term 
memory storage (Cammarota et al., 2008; Kelly et al., 2003). There is also accumulating 
evidence implicating the ERK pathway in behavioral responses to addictive drugs such as 
METH and cocaine (Mizoguchi et al 2004; Valjent et al 2000). ERK expression is especially 
abundant in the mesocorticolimbic DA system, a distribution that underscores the 
importance of the ERK signaling cascade in mediating DA function (Valjent et al., 2004). 
ERK signaling is also known to be critically linked to DA D1 receptor activation, which 
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couples with Gs proteins leading to cAMP and PKA cascade activation (Valjent et al., 2000; 
Nagai et al., 2007). Activated ERK can promote the expression of genes associated with 
memory and learning, in part, by activating transcription factors such as CREB and Elk-1, 
which in turn activate gene transcription involved in synaptic and neuronal plasticity such as 
c-Fos, Zif268, etc. (Cammarota et al., 2008; Zhai et al., 2008). Our results indicate that 
modafinil modulates ERK phosphorylation in mPFC in a dose-dependent manner, which 
might be related to modafinil’s ability to enhance DA neurotransmission and stimulation of 
D1 receptors (Young and Geyer, 2010).
It is well known that repeated exposure to drugs of abuse results in a progressive and long-
lasting enhancement of the locomotor response, a phenomenon termed psychomotor (or 
locomotor) sensitization (Robinson and Berridge, 1993). It is also of interest to discuss our 
results showing that modafinil induced a cross-sensitization effect with METH. We showed 
that the same modafinil dose that enhanced visual retention in METH-treated mice, 90 
mg/Kg, also elicited a cross-sensitization effect in locomotion. A previous study in mice also 
found locomotor cross-sensitization between METH and modafinil assessed by challenging 
modafinil -pretreated mice with 1 mg/Kg METH, and METH-pretreated mice with 50 
mg/Kg modafinil (Soeiro et al., 2012). Our results on cross-sensitization between METH 
and modafinil raise the possibility that neuroadaptations induced by METH and evidenced 
by acute administration of modafinil might be related to the beneficial effects of modafinil 
on cognition.
There is some discrepancy in the role of novelty-mediated ERK signaling in the 
hippocampus, since ERK hyperphosphorylation after training session was observed in rats 
(Kelly et al., 2003), but not in mice (Kamei et al., 2006). In the present study, we found no 
novelty-mediated changes in ERK phosphorylation in the hippocampus of the experimental 
groups, in agreement with the studies performed by Kamei and co-workers (2006) in ICR 
mice. A possible explanation for the differences observed between species may be that the 
study performed in rats analyzed specifically the dentate gyrus and CA1 regions of the 
hippocampus, while the studies in mice where performed on the whole structure, which may 
have diluted the differences. Nonetheless, our results are in agreement with recent reports 
showing that the hippocampus, together with the perirhinal and the prefrontal cortices, is 
involved in the object location and object-in-place tasks, which have a spatial processing 
component, but not in the novel object recognition task (Forwood et al., 2005; Barker and 
Warburton, 2011). We also found no novelty-mediated ERK phosphorylation in the NAc of 
the experimental groups. The role of NAc in novelty processing is controversial, with reports 
indicating a NAc role only in tasks that involve spatial processing (Mele et al., 2004; Nelson 
et al., 2010), and reports indicating that the NAc also participates in visual object (non-
spatial) processing (Sargolini et al., 2003). Our results indicate that, whether or not the NAc 
is involved in novelty processing, the ERK pathway in this structure was not affected by 
either METH or modafinil.
Imaging studies show that drug abusers have marked decreases in DA receptors and DA 
release. This decrease in DA function is associated with reduced activity in brain areas that 
mediate inhibitory control and executive function, such as the cingulate gyrus and the 
dorsolateral PFC. Deficits in DA activity, linked with prefrontal and striatal deregulation, 
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play a central role in the loss of control and compulsive drug intake behavior (Volkow et al., 
2009). Although the mechanisms underlying modafinil-induced improvements in prefrontal 
function and cognitive performance have yet to be delineated, our results further support the 
notion that modafinil represents an effective therapeutic intervention aimed at restoring brain 
dopaminergic tone, and therefore restoring intracellular pathways like the MAPK-ERK 
pathway in the PFC. Moreover, results from the present study further support the hypothesis 
that drugs that could modulate ERK pathways might in turn be useful for the treatment of 
the cognitive consequences of drug abuse. Specifically, our results point to modafinil as a 
good candidate for the treatment of METH dependence, considering modafinil therapy as an 
agonist-like replacement therapy (Herin et al., 2010).
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• Methamphetamine produces recognition memory deficits and failures 
in cortical ERK signaling.
• Acute modafinil administration improved methamphetamine-induced 
memory deficits.
• Modafinil restored ERK signaling in medial prefrontal cortex induced 
by novelty.
• We report modafinil protective properties against methamphetamine 
harmful effects.
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Figure 1. Schematic representations of the experimental treatments and behavioral analysis
A) Male C57BL/6 mice were subjected to sub-chronic treatment with saline or METH 1 
mg/Kg, sc, once a day for 7 consecutive days. On day 4 after sub-chronic treatment, mice 
received vehicle or MOD 90 or 30 mg/Kg, ip, 1 hr before behavioral analysis. B) METH 
withdrawal mice were habituated to the object recognition arena 5 min a day for 3 
consecutive days. On withdrawal day 4, mice performed the Novel Object Recognition 
(NOR) task or were evaluated for the Novelty effect. For the NOR task, mice performed a 
training session in which they were allowed to freely explore two equal objects for 10 min, 
and 24 hrs later (day 5) performed a 5 min retention session, where one of the familiar 
objects was replaced by a novel object. To evaluate the Novelty effect, mice performed a 10 
min Novelty session where they were allowed to explore two equal novel objects and 
euthanized immediately. Control mice were placed in the arena in the absence of objects and 
the same procedure was performed.
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Figure 2. Effect of chronic METH withdrawal on exploratory activity
Mice were treated with vehicle or METH (1 mg/Kg, sc, once a day for 7 days), and on 
withdrawal were placed in an open-top arena in a 5 min habituation session for 3 
consecutive days. A) Locomotion, *: Day 1 different from Day 2 and Day 3 (p<0.05). B) 
Time in center, *: vehicle different from METH in Day 2. Exploratory activity during 
METH withdrawal was evaluated using Ethovision XT 7.0 tracking software (Noldus, 
Leesburg, Virginia). Repeated measures two-way ANOVA - Bonferroni. Values indicate 
mean ± SEM (N=8–9),
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Figure 3. Effect of MOD on METH-induced cognitive impairment in a Novel Object Recognition 
task
A and B) Exploratory preference in training and retention sessions of chronic vehicle- and 
METH-treated mice, injected on withdrawal day 4 with vehicle or MOD 90 and 30 mg/Kg, 
respectively; the dotted line at 50% indicates equal preference for both familiar and novel 
object, indicative of visual memory impairment. MOD 90 mg/Kg retention session: ANOVA 
- Bonferroni. MOD 30 mg/Kg retention session: Kruskal Wallis ANOVA on ranks. C and D) 
Total exploration time in training and retention sessions of chronic vehicle- and METH-
treated mice, injected on withdrawal day 4 with vehicle or MOD 90 and 30 mg/Kg, 
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respectively. E and F) Locomotion in training and retention sessions of chronic vehicle- and 
METH-treated mice, injected on withdrawal day 4 with vehicle or MOD 90 and 30 mg/Kg, 
respectively. Time spent exploring objects and locomotion was analyzed with Ethovision XT 
7.0 (Leesburg, Virginia). ANOVA - Bonferroni. Values indicate mean ± SEM (N=12–22), 
different letters: p<0.05.
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Figure 4. Effect of MOD on METH-induced changes in locomotion after novelty exposure
On withdrawal day 4 after chronic vehicle or METH treatment (1 mg/Kg, sc, once a day for 
7 days) mice received acute modafinil and 1 hr later performed a 10 min Novelty session in 
which they were allowed to explore two equal novel objects and euthanized immediately. 
Control mice were placed in the arena in the absence of objects and the same procedure was 
performed. A) Modafinil 30 mg/Kg, B) Modafinil 90 mg/Kg. Locomotion was analyzed 
with Ethovision XT 7.0 (Leesburg, Virginia). Two way ANOVA - Bonferroni. Values 
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indicate the mean ± SEM (N=4– 9), different letters: p<0.05, *: different from METH-MOD 
control.
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Figure 5. Effect of modafinil on METH-induced changes in ERK phosphorylation in the mPFC 
after novelty exposure
On withdrawal day 4 after chronic vehicle or METH treatment (1 mg/Kg, sc, once a day for 
7 days) mice received acute MOD and 1 hr later performed a 10 min novelty session, then 
euthanized immediately (novelty group). Control mice were placed in the arena in the 
absence of objects and the same procedure was performed (control group). A) Modafinil 30 
mg/Kg. B) Modafinil 90 mg/Kg. Two way ANOVA followed by planned contrasts between 
control and novelty within each treatment. Values indicate the mean ± SEM (N=4–9), *: 
significantly different from control of the respective treatment.
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Figure 6. Effect of MOD on METH-induced changes in ERK phosphorylation in the 
hippocampus and nucleus accumbens (NAc) after novelty exposure
On withdrawal day 4 after chronic vehicle or METH treatment (1 mg/Kg, sc, once a day for 
7 days) mice received acute modafinil 90 mg/Kg and 1 hr later performed a 10 min novelty 
session, then were euthanized immediately (novelty group). Control mice were placed in the 
arena in the absence of objects and the same procedure was performed (control group). A) 
Hippocampus, B) Nucleus accumbens (NAc). Two way ANOVA. Values indicate the mean ± 
SEM (N=3–5).
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